The outcome was broadly what investors would expect from a scheduled annual meeting. Shareholders approved the director slate, auditors, executive compensation, and the routine Irish-law authorities for share issuance and pre-emption rights; the filing adds no new operating, financial, or strategic information (Item 5.07). The meeting had a 92.25% quorum (Item 5.07).
| Matter | Filing result |
|---|---|
| Board nominees elected | 9 of 9 (Item 5.07) |
| Board size after meeting | 9 directors (Item 5.07) |
| Lowest director support | Cynthia L. Feldmann: 74,792,537 for; 11,102,333 against (Director election results) |
| Executive compensation approved | 77,639,271 for; 8,493,021 against (Item 5.07) |
| Authority to issue authorized shares renewed | 89,209,571 for; 681,087 against (Item 5.07) |
| Pre-emption-right opt-out renewed | 86,256,858 for; 3,483,603 against (Item 5.07) |
The only notable governance detail was the board reduction and uneven director support. The board is now formally set at nine members, while Feldmann and Sohi received materially more opposition than the rest of the slate; however, both were still elected, so the filing does not show a failed governance vote or an immediate leadership change (Director election results).
Net read: confirmation, not a catalyst. The votes were largely procedural and likely anticipated ahead of the July 31, 2026 meeting, making this a priced-in governance update rather than a fresh positive or negative surprise. The renewed share-issuance authority creates future flexibility but does not itself announce dilution or an equity offering (Item 5.07).
Read the original 8-K on SEC EDGAR ↗